Handelsbanken Fonder AB Sells 18,835 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Handelsbanken Fonder AB lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.7% in the fourth quarter, Holdings Channel reports. The firm owned 54,346 shares of the biopharmaceutical company’s stock after selling 18,835 shares during the quarter. Handelsbanken Fonder AB’s holdings in Alnylam Pharmaceuticals were worth $12,788,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ALNY. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $61,160,000. Strategic Financial Concepts LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $41,529,000. Eventide Asset Management LLC lifted its stake in Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after acquiring an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Finally, Telemark Asset Management LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at $27,503,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $250.59 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm has a market cap of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35. The firm’s 50-day simple moving average is $254.14 and its 200 day simple moving average is $263.03. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,356 shares of company stock valued at $22,498,551 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have commented on ALNY. Chardan Capital reiterated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Scotiabank cut their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. Finally, Barclays increased their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $299.48.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.